Efficacy Of Sacituzumab Govitecan (Sg) By Trophoblast Cell Surface Antigen 2 (Trop-2) Expression In Patients (Pts) With Metastatic Urothelial Cancer (Muc)

Trop-2, an epithelial cell surface antigen highly expressed in many solid tumors, has been associated with poor outcomes. SG, an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to an SN-38 payload via a proprietary hydrolyzable linker has received accelerated FDA approval in mUC based on data from the TROPHY U-01 study. Data from cohorts 1 and 2 of the study demonstrated an objective response rate [ORR] of 27% and 29%, respectively, in pretreated populations. This pooled (cohorts 1 and 2) analysis evaluated the levels of Trop-2 expression and their association with outcomes.